Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
- Conditions
- MonkeypoxHIV Coinfection
- Interventions
- Other: No intervention
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 2000
- Registration Number
- NCT05965427
- Locations
- 🇫🇷
Hôpital Bichat Claude Bernard, Paris, France
🇫🇷Hôpital Pitié-Salpêtrière, Paris, France
🇬🇧Chelsea and Westminster Hospital, London, United Kingdom
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
- Conditions
- COVID-19Coronavirus InfectionSARS-CoV2 Infection
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 28
- Registration Number
- NCT05593770
- Locations
- 🇿🇦
Global Clinical Trials (Pty) Ltd, Pretoria, South Africa
🇿🇦Clinical HIV Research Unit - Helen Joseph Hospital (WITS CHRU), Johannesburg, South Africa
🇪🇸Hospital Clinic Barcelona, Barcelona, Villarroel, Spain
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
- Conditions
- HIV-1-infectionCOVID-19
- Interventions
- Other: COVID-19Other: HIV-1 infection
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 2598
- Registration Number
- NCT05481216
- Locations
- 🇧🇪
CHU Saint Pierre, Brussels, Belgium
🇫🇷Hôpital Européen Marseille, Marseille, France
🇫🇷Hôpital Saint Louis, Paris, France
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
- Conditions
- HIV I Infection
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 399
- Registration Number
- NCT05421806
- Locations
- 🇫🇷
Hopital Universitaire Pitie-Salpetriere, Paris, France
🇫🇷CHU de Nantes, Nantes, France
🇫🇷St Louis Hospital, Paris, France
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 140
- Registration Number
- NCT05349838
- Locations
- 🇧🇪
Institute of Tropical Medecine, Antwerp, Belgium
🇩🇪University Bonn, Bonn, Germany
🇫🇷Pitié-salpêtrière Hospital, Paris, France
Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 451
- Registration Number
- NCT04847622
- Locations
- 🇫🇷
CHU de Nantes, Nantes, France
🇫🇷Hospital Lariboisiere, Paris, France
🇫🇷Hopital Saint-Louis, Paris, France
The Late Presenter Treatment Optimisation Study
- First Posted Date
- 2018-10-04
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- NEAT ID Foundation
- Target Recruit Count
- 447
- Registration Number
- NCT03696160
- Locations
- 🇫🇷
Groupe Hospitalier Sud Ile-de-France (Melun), Melun, France
🇧🇪Institute of Tropical Medicine, Antwerp, Belgium
🇫🇷Hôpital Gui de Chauliac, Montpellier, France